Related Experiment Video
Updated: May 21, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Emerging anticoagulants
B Kennedy1, F S Gargoum, L Kennedy
1Department of Respiratory Medicine, Mercy University Hospital, Grenville Place, Cork, Ireland.
Current Medicinal Chemistry
|June 12, 2012
Summary
Novel anticoagulants, including factor Xa and thrombin inhibitors, offer improved safety and efficacy over traditional options like warfarin and heparin. These newer agents promise easier administration and predictable outcomes for preventing blood clots and stroke.
Area of Science:
- Pharmacology
- Hematology
- Cardiovascular Medicine
Background:
- Traditional anticoagulants like warfarin and heparin have limitations including adverse effects and need for monitoring.
- Advances in understanding hemostasis and the coagulation cascade have driven the development of novel anticoagulants.
- Newer agents aim for improved safety, efficacy, pharmacodynamics, and ease of administration compared to older treatments.
Purpose of the Study:
- To review emerging novel anticoagulants.
- To discuss their applications in venous thromboembolism prophylaxis and treatment.
- To explore their role in stroke prevention for nonvalvular atrial fibrillation and in coronary artery disease.
Main Methods:
- Review of scientific literature on novel anticoagulant agents.
- Analysis of pharmacokinetic and pharmacodynamic profiles.
- Evaluation of clinical applications and comparative efficacy.
Main Results:
- Development of direct and indirect factor Xa inhibitors (e.g., apixaban, rivaroxaban, fondaparinux).
- Development of direct thrombin inhibitors (e.g., dabigatran etexilate, bivalirudin).
- These novel agents offer rapid onset, stable profiles, and reduced monitoring needs.
Conclusions:
- Novel anticoagulants represent a significant advancement over traditional therapies.
- They provide effective options for venous thromboembolism, stroke prevention in atrial fibrillation, and coronary artery disease.
- Further research and clinical adoption are expected to enhance patient outcomes.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...